11.4 Pulmonary Vein Isolation (PVI) for AFib & Ventricular Tachycardia Ablation

11.4 Pulmonary Vein Isolation (PVI) for AFib & Ventricular Tachycardia Ablation

Catheter ablation of complex cardiac arrhythmias—specifically atrial fibrillation (AFib) and ventricular tachycardia (VT)—demands high-level technical precision, comprehensive three-dimensional electroanatomic mapping, and rigorous electrophysiological validation.

While focal supraventricular reentrant tachycardias rely on discrete targets (such as the slow pathway or accessory pathways), AFib and scar-related VT involve extensive anatomical substrates and macroreentrant circuits. For the Registered Cardiac Electrophysiology Specialist (RCES), mastering the biophysics of tissue injury, advanced catheter navigation, anticoagulation safety, and definitive conduction endpoints is vital for procedural efficacy and patient safety.

---

Pulmonary Vein Isolation (PVI) for Atrial Fibrillation

Pathophysiological Basis: The Arrhythmogenic Pulmonary Vein Sleeves

Seminal discoveries by Michel Haïssaguerre and colleagues in the late 1990s established that in over 90% of patients with paroxysmal atrial fibrillation, the rapid ectopic triggers that initiate and maintain AF originate within the pulmonary veins (PVs). Muscular sleeves of left atrial myocardium extend over the outer adventitial surface of the four pulmonary veins:

• Left Superior Pulmonary Vein (LSPV)
• Left Inferior Pulmonary Vein (LIPV)
• Right Superior Pulmonary Vein (RSPV)
• Right Inferior Pulmonary Vein (RIPV)

These myocardial sleeves exhibit unique electrophysiological properties, including short action potential durations, abrupt fiber orientation changes, and marked resting membrane instability. This substrate promotes delayed afterdepolarizations, early afterdepolarizations, microreentry, and rapid burst firing that cascades into disorganized fibrillatory conduction across the left atrium.

                                  [Left Atrium (LA)]
                                          |
                  +-----------------------+-----------------------+
                  |                                               |
      [Left Pulmonary Veins]                          [Right Pulmonary Veins]
     (LSPV & LIPV Ipsilateral)                       (RSPV & RIPV Ipsilateral)
                  |                                               |
         [Wide Antral Line]                              [Wide Antral Line]
     (WACA: Outside PV Ostia)                        (WACA: Outside PV Ostia)
                  |                                               |
   +==============X==============+                 +==============X==============+
   |  Isolated PV Sleeves:       |                 |  Isolated PV Sleeves:       |
   |  - Entrance Block Achieved  |                 |  - Entrance Block Achieved  |
   |  - Exit Block Confirmed     |                 |  - Exit Block Confirmed     |
   |  - Dormant Conduction Nil   |                 |  - Phrenic Nerve Protected  |
   +=============================+                 +=============================+

Wide Antral Circumferential Ablation (WACA)

Early PVI techniques involved ablating directly within the tubular ostia of the pulmonary veins. This historical approach resulted in high rates of severe pulmonary vein stenosis due to thermal cicatrization, vascular hyperplasia, and luminal narrowing.

Modern radiofrequency ablation standardly employs Wide Antral Circumferential Ablation (WACA):

• Continuous, transmural lines of ablation encircle the ipsilateral pulmonary vein pairs together (left-sided pair: LSPV and LIPV; right-sided pair: RSPV and RIPV) along the atrial antrum, situated well outside (5 to 15 mm) the true venous ostia.
• WACA isolates the arrhythmogenic triggers within the veins while simultaneously debulking adjacent antral ganglionated plexi (GP) and modifying the surrounding atrial substrate, yielding higher long-term sinus rhythm maintenance and virtually eliminating PV stenosis.

Transseptal Catheterization & Anticoagulation Management

Access to the left atrium requires percutaneous transseptal puncture across the fossa ovalis from the right femoral vein:

• Guidance & Safety: Performed using a transseptal needle (e.g., Brockenbrough or radiofrequency NRG needle) and a long guiding sheath (e.g., Preface or steerable Agilis sheath) under simultaneous fluoroscopy and intracardiac echocardiography (ICE). ICE confirms tenting of the fossa ovalis in the mid-fossa region, rules out proximity to the aortic root or LA free wall, and detects pericardial effusion in real time.
• Strict Anticoagulation Protocol: Left atrial catheterization introduces high thrombogenic risk. Systemic anticoagulation with intravenous unfractionated heparin is initiated either immediately prior to transseptal puncture or immediately upon left atrial access (initial bolus of 50 to 100 units/kg). The Activated Clotting Time (ACT) must be measured every 20 to 30 minutes and maintained strictly between 300 and 350 seconds throughout the left heart dwell time to prevent left atrial thrombus formation and thromboembolic stroke.

Electrophysiological Validation of PVI: Entrance & Exit Block

Definitive electrical isolation of all four pulmonary veins requires rigorous proof of bidirectional conduction block:

1. Validation of Entrance Block (LA to PV):

   • A multi-electrode circular mapping catheter (such as a Lasso, Pentaray, or Advisor catheter) is positioned at the antral ostium of the pulmonary vein.
   • Criteria for Entrance Block:
     • During sinus rhythm or coronary sinus pacing, all high-frequency pulmonary vein potentials (PVPs) recorded on the circular catheter must completely disappear or become dissociated.
     • Dissociated PV Automaticity: A classic proof of complete entrance block occurs when the circular catheter records independent, slow, rhythmic electrical spikes within the vein (PV pacemaker automaticity or PV fibrillatory firing) that fail to conduct outward into the left atrium or affect the surface ECG.
   • Distinguishing Far-Field Signals: Low-amplitude, blunt signals often persist on the circular catheter despite complete isolation, representing far-field electrical activity from adjacent structures (e.g., the left atrial appendage [LAA] on LSPV recordings, or the superior vena cava [SVC] on RSPV recordings). Differential pacing is essential: pacing the LAA will advance the LAA far-field potential while true PV potentials are unchanged or delayed, proving the persistent signal is benign far-field.

2. Validation of Exit Block (PV to LA):

   • Proving entrance block alone is insufficient; unidirectional conduction block can occur.
   • Criteria for Exit Block: The circular mapping catheter is used to deliver high-output pacing (typically 10 mA output at a 2.0 ms pulse width) from every adjacent bipolar pair within the pulmonary vein.
   • Verification: Pacing must achieve local capture of the PV tissue (confirmed by capture spikes on the circular catheter) while completely failing to conduct out to capture the left atrium or surface ECG. Failure to pace-capture the vein due to local inexcitability also satisfies exit block criteria.

3. Pharmacological Provocation (Adenosine & Isoproterenol):

   • Adenosine Challenge: Following apparent electrical isolation, an intravenous bolus of adenosine (12 to 18 mg) is administered. Adenosine transiently hyperpolarizes resting membrane potentials, temporarily restoring conduction across damaged, non-transmural myocardial tissue bridges ("dormant conduction"). Transient reappearance of PV potentials or acute reconnection during adenosine unmasks incomplete lesions requiring targeted supplemental ablation.
   • Isoproterenol Infusion: Titrated high-dose isoproterenol (5 to 20 mcg/min) is infused to elicit non-pulmonary vein triggers (e.g., from the superior vena cava, coronary sinus, crista terminalis, or left atrial posterior wall) that may provoke recurrent atrial fibrillation.

---

Cryoballoon PVI Technique & Safety Monitoring

Cryoballoon ablation (using a 28 mm second- or fourth-generation balloon, e.g., Arctic Front Advance) delivers circumferential freezing via the Joule-Thomson effect (evaporative cooling of pressurized nitrous oxide, $N_2O$):

                                  [Right Phrenic Nerve]
                                            |
                         +------------------+------------------+
                         |                                     |
                  [RSPV / RIPV Antrum]                  [SVC Pacing Site]
                         |                                     |
                 (Cryoballoon Freeze)               (Continuous Diaphragmatic Pacing)
                         |                                     |
                         v                                     v
            [Monitor Diaphragmatic CMAP]            [Palpate Abdominal Twitch]
                         |
                         +---------> If CMAP Drops >=30%: 
                                     IMMEDIATELY ABORT FREEZE (<1 sec)!

Cryokinetics & Quality Parameters

1. Balloon Occlusion Assessment: Prior to freezing, radiographic contrast is injected through the central lumen of the balloon into the vein under fluoroscopy. Occlusion is graded from 1 to 4:
   • Grade 1-2: Substantial contrast leak back into the LA (poor contact).
   • Grade 3: Minor leak at one quadrant.
   • Grade 4: Complete contrast retention with no backflow into the LA, indicating 360° circumferential antral contact.
2. Time to Isolation (TTI): Recording real-time PV potentials during the freeze using an inner lumen circular mapping catheter (Achieve). A TTI < 60 seconds strongly predicts durable, permanent transmural lesion formation. If TTI exceeds 60 seconds, the freeze is typically aborted and the balloon reseated.
3. Nadir Temperature: Optimal freezing nadir ranges between -40°C and -50°C. Temperatures colder than -55°C to -60°C risk deep collateral thermal injury to the esophagus and must be aborted.
4. Esophageal Protection: To prevent atrio-esophageal fistula (a lethal complication with >50% mortality), a multi-sensor luminal esophageal temperature (LET) probe is placed. Freezing is stopped immediately if esophageal temperature drops below 15°C to 20°C.
5. Phrenic Nerve Monitoring (The Paramount Safety Protocol):
   • The right phrenic nerve courses immediately adjacent to the anterior and superior antra of the right pulmonary veins (RSPV and RIPV).
   • During all right-sided cryoballoon freezes, the right phrenic nerve is continuously paced from the high SVC or right subclavian vein (at 2000 to 3000 ms cycle length, 10 to 20 mA).
   • The operator continuously palpates right diaphragmatic excursion while monitoring the Compound Motor Action Potential (CMAP) recorded via surface ECG electrodes on the right subcostal margin.
   • Mandatory Abort Criterion: Any reduction in the strength of the diaphragmatic twitch or a >= 30% reduction in CMAP amplitude mandates immediate abortion of the freeze (<1 second) via rapid deflation to prevent permanent diaphragmatic paralysis.

---

Ventricular Tachycardia (VT) Ablation

Pathophysiological Substrate & Mechanisms

Ventricular tachycardia in patients with structural heart disease arises primarily from macroreentry within areas of myocardial scar:

1. Ischemic Cardiomyopathy (ICM): Scar resulting from prior myocardial infarction is predominantly subendocardial to transmural, characterized by dense collagenous fibrosis interspersed with surviving viable myocardial bundles. These surviving bundles form protected, slowly conducting isthmuses that sustain reentry.
2. Non-Ischemic Cardiomyopathy (NICM): Scar patterns (e.g., in dilated cardiomyopathy, myocarditis, sarcoidosis, or ARVC) are typically patchy, mid-myocardial, or subepicardial, often clustering around the mitral or aortic valve fibrous annuli. NICM frequently requires epicardial access via percutaneous subxiphoid puncture to reach critical circuits.

Activation Mapping vs Substrate Mapping

• Activation Mapping: Entails mapping the chamber during ongoing, sustained VT to identify the full sequence of electrical activation. However, in over 70% to 80% of clinical cases, sustained VT is hemodynamically unstable (causing profound hypotension, syncope, or degenerating into ventricular fibrillation) or non-sustained, making prolonged activation mapping impossible.
• Substrate-Based Mapping: The primary approach in modern EP practice, performed entirely during stable baseline sinus rhythm or right ventricular pacing. A high-density 3D electroanatomic voltage map is created:
  • Dense Core Scar: Bipolar voltage < 0.5 mV (electrically inert fibrous tissue).
  • Border Zone / Scar Penumbra: Bipolar voltage 0.5 to 1.5 mV (heterogeneous zone containing surviving channels of viable myocardium).
  • Normal Healthy Myocardium: Bipolar voltage > 1.5 mV.

          [Normal Ventricular Myocardium (Bipolar Voltage > 1.5 mV)]
                                      |
        +-----------------------------+-----------------------------+
        |                                                           |
        v                                                           v
  [Scar Border Zone (0.5 - 1.5 mV)]                   [Dense Core Scar (< 0.5 mV)]
  - Surviving Myocardial Bundles                       - Electrically Inert Fibrosis
  - Late Potentials (LPs) Recorded                    - Unexcitable Central Obstacle
  - Local Abnormal Ventricular Activity (LAVA)                      |
        |                                                           |
        +---> [CRITICAL REENTRANT ISTHMUS] <------------------------+
              - Protected Slow Conduction Channel
              - Diastolic Potentials during VT
              - Entrainment with Concealed Fusion (PPI - TCL < 30 ms)
              - Pace Map Match: 12/12 Lead Concordance with S-QRS Delay

Identifying the Critical Reentry Isthmus

Successful VT ablation requires targeted elimination of the critical conducting isthmus within the scar border zone. Electrophysiological markers include:

1. Late Potentials (LPs): Distinct, high-frequency, low-amplitude potentials that occur after the end of the surface QRS complex during sinus rhythm or paced rhythm. LPs reflect slow, delayed conduction through isolated, surviving myocardial channels embedded in fibrous tissue.
2. Local Abnormal Ventricular Activity (LAVA): Sharp, fractionated potentials that can occur throughout the cardiac cycle (before, during, or after the far-field ventricular deflection) representing poorly coupled viable tissue within the scar.
3. Diastolic Potentials: When VT is hemodynamically tolerated, mapping within the protected isthmus reveals isolated potentials occurring during electrical diastole (the isoelectric interval between successive QRS complexes).
4. Pace Mapping: Delivering pacing pulses at putative isthmus exit sites during sinus rhythm. A 12/12 lead match between the paced QRS morphology and the clinical 12-lead VT QRS indicates the catheter is at the exit site. A long stimulus-to-QRS interval (S-QRS > 40 ms) confirms the pacing site is within a slowly conducting channel.
5. Entrainment with Concealed Fusion: The gold standard maneuver for confirming catheter position within the critical isthmus during stable VT:
   • Pacing is delivered at a cycle length 10 to 20 ms shorter than the tachycardia cycle length (TCL).
   • Concealed Fusion: The surface QRS morphology during pacing is identical to the spontaneous VT QRS (because the entire chamber is activated via the intrinsic isthmus exit), with an S-QRS interval matching the intrinsic electrogram-to-QRS delay.
   • Post-Pacing Interval (PPI): The interval from the last pacing stimulus to the next local electrogram at the pacing site. If the catheter is within the critical circuit, the PPI - TCL is strictly < 30 ms.

Procedural Endpoints for VT Ablation

1. Complete Non-Inducibility of VT: Programmed ventricular stimulation (using up to three extrastimuli, S2, S3, S4, delivered at multiple drive cycle lengths from both the RV apex and RVOT/LV) fails to induce clinical or non-clinical sustained monomorphic VT.
2. Substrate Homogenization / Scar Dechanneling: Complete abolition of all recorded late potentials, LAVAs, and conduction channels within the scar and border zone, verified by high-density remap.

Summary Table: PVI for AFib vs Scar-Related VT Ablation

| Procedural Dimension | Pulmonary Vein Isolation (AFib) | Ventricular Tachycardia (Scar Substrate) | | :--- | :--- | :--- | :--- | | Primary Anatomical Target | Antrum of ipsilateral pulmonary vein pairs (WACA) | Border zone channels ($0.5-1.5\text{ mV}$) within dense scar ($<0.5\text{ mV}$) | | Energy Delivery Modality | Open-irrigated RF (30-45 W) or Cryoballoon (-40°C to -50°C) | Irrigated RF (35-50 W) with contact force (10-25 g) | | Anticoagulation Target | IV Heparin; ACT maintained strictly at 300 to 350 seconds | IV Heparin; ACT 250-300 s (LV retrograde/transseptal access) | | Key Diagnostic Tools | Circular mapping catheter (Lasso/Pentaray), ICE, Esophageal probe | High-density multi-electrode mapping catheter, 3D electroanatomic system | | Primary Diagnostic Markers | Elimination of PV potentials; dissociated PV automaticity | Late potentials (LPs), LAVA, diastolic potentials, 12/12 pace map | | Definitive Conduction Endpoint | Proven Entrance Block and Exit Block (10 mA / 2 ms pacing) | Concealed fusion (PPI - TCL < 30 ms); complete scar homogenization | | Pharmacological Challenge | Adenosine (12-18 mg) to unmask dormant conduction | Isoproterenol or epinephrine to provoke non-clinical or clinical VT | | Primary Safety Hazard | Phrenic nerve injury (CMAP drop $\ge 30%$ aborts freeze); Esophageal fistula | Ventricular perforation / tamponade; complete AV block (septal scar) |